Serotonin syndromeMANAGEMENT

TOXICOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

649 items

☷ Legend

01Approach to the Critical Patient/attcp68

Immediate priorities

›Stabilization priorities

›Airway risk

›Rapidly worsening agitation

›Refractory hyperthermia

›Progressive rigidity

›Breathing support

›Hypoventilation after sedatives

›Aspiration risk with vomiting

›Circulation support

›Hypotension from dehydration

›Shock from severe hyperthermia

›Trigger recognition

›Recent serotonergic exposure

›Dose increase

›Drug interaction

›Overdose

›Time zero

›Symptom onset within 24 hours of exposure change

Severity stratification

›Severity categories

›Mild

›Tremor

›Hyperreflexia

›Mild agitation

›Afebrile or low-grade fever

›Moderate

›Marked agitation

›Sustained clonus

›Hyperthermia 38.0-40.0 C

›Autonomic instability

›Severe

›Hyperthermia >40.0 C

›Delirium

›Generalized rigidity

›Rapid clinical deterioration

›Seizure

›Coma

Key bedside signs

›Neuromuscular hyperactivity pattern

›Inducible clonus

›Ankle clonus

›Ocular clonus

›Spontaneous clonus

›Sustained rhythmic jerks

›Hyperreflexia

›Lower extremities predominant

›Tremor

›Coexisting hyperreflexia

›Rigidity

›Severe cases

›Mydriasis

›With diaphoresis

›Diaphoresis

›With agitation

Escalation triggers

›Immediate escalation criteria

›Temperature >= 40.0 C

›Resuscitation bay

›Critical care consult

›Refractory agitation

›High-dose benzodiazepine requirement

›Seizure

›Continuous monitoring

›Rhabdomyolysis concern

›Rising creatine kinase trend

›Metabolic acidosis

›Rising lactate

›Organ failure signs

›Oliguria

›Hypoxia

›Coagulopathy

02History/hx93

Exposure timeline

›Serotonergic exposure pattern

›New serotonergic medication

›Start date

›First dose time

›Dose increase

›Date and magnitude

›Co-ingestion

›Multiple serotonergic agents

›Overdose

›Estimated amount

›Time of ingestion

›Drug interaction

›MAOI combined with SSRI or SNRI

›MAOI combined with linezolid

›MAOI combined with methylene blue

›Onset window

›Symptoms within 6 hours

›Symptoms within 24 hours

Medication and substance list

›High-risk agents

›SSRIs

›Fluoxetine

›Sertraline

›Citalopram

›Escitalopram

›Paroxetine

›Fluvoxamine

›SNRIs

›Venlafaxine

›Desvenlafaxine

›Duloxetine

›MAOIs

›Phenelzine

›Tranylcypromine

›Selegiline

›Isocarboxazid

›Serotonergic analgesics

›Tramadol

›Meperidine

›Fentanyl

›Methadone

›Serotonergic antiemetics

›Ondansetron

›Metoclopramide

›Antimicrobials

›Linezolid

›Migraine therapies

›Triptans

›OTC and supplements

›Dextromethorphan

›St John’s wort

›Recreational substances

›MDMA

›Cocaine

›Amphetamines

›Other

›Lithium

›Buspirone

›Trazodone

›Mirtazapine

Symptom pattern

›Core symptom clusters

›Mental status change

›Anxiety

›Agitation

›Delirium

›Confusion

›Autonomic hyperactivity

›Diaphoresis

›Tachycardia

›Hypertension

›Hyperthermia

›Diarrhea

›Vomiting

›Neuromuscular hyperactivity

›Tremor

›Clonus

›Hyperreflexia

›Myoclonus

›Rigidity

Risk factors and pitfalls

›Higher risk contexts

›Polypharmacy

›Multiple serotonergic prescriptions

›Recent hospitalization

›Linezolid exposure

›Methylene blue exposure

›Medication adherence changes

›Restart after interruption

›Drug metabolism modifiers

›CYP inhibitors co-prescribed

›Diagnostic pitfalls

›Attribution to anxiety alone

›Mislabeling as withdrawal

›Missing ocular clonus

›Focusing on fever without clonus

03Physical Exam/exam51

Vital signs and monitoring

›Physiologic instability

›Temperature trend

›Hyperthermia threshold awareness

›Heart rate

›Persistent tachycardia

›Blood pressure

›Labile hypertension

›Hypotension after sedation

›Respiratory rate

›Hyperventilation

›Oxygen saturation

›Aspiration risk marker

Neurologic exam focus

›Neuromuscular findings

›Clonus

›Spontaneous clonus

›Inducible clonus

›Ocular clonus

›Reflexes

›Hyperreflexia

›Lower extremity predominance

›Tone

›Rigidity

›Increased tone

›Tremor

›Fine tremor

›Myoclonus

›Multifocal jerks

›Pupils

›Mydriasis

›Mental status

›Agitation

›Delirium

›Coma

Autonomic and systemic findings

›Autonomic features

›Diaphoresis

›Profuse sweating

›Skin

›Flushed

›GI findings

›Hyperactive bowel sounds

›Diarrhea

›Complication screening

›Trauma signs

›Falls during agitation

›Compartment concern

›Severe muscle pain with swelling

PITFALLS

›Exam pitfalls

›Clonus absent after heavy sedation

›Rigidity can mimic NMS in severe cases

›Hyperreflexia may be subtle in older adults

›Co-ingestions can blur typical pattern

04Differential Diagnosis/ddx51

Life threats and mimics

›Hyperthermia syndromes

›Neuroleptic malignant syndrome

›Dopamine antagonist exposure

›Lead-pipe rigidity

›Slower onset over days

›ICD-10 G21.0

›Malignant hyperthermia

›Volatile anesthetic exposure

›Succinylcholine exposure

›Severe rigidity

›Heat stroke

›Environmental heat exposure

›Exertional collapse

›Toxicologic mimics

›Anticholinergic toxidrome

›Dry skin

›Urinary retention

›Absent bowel sounds

›Sympathomimetic toxidrome

›Cocaine

›Amphetamines

›Prominent diaphoresis

›Withdrawal syndromes

›Alcohol withdrawal

›Benzodiazepine withdrawal

›Infectious and CNS etiologies

›Meningitis

›Neck stiffness

›Photophobia

›Encephalitis

›Focal deficits

›Seizure

›Endocrine and metabolic

›Thyroid storm

›Hyperthyroid history

›Goiter

›Hypoglycemia

›Altered mental status

›Neurologic emergencies

›Status epilepticus

›Persistent convulsive activity

›Intracranial hemorrhage

›Focal deficit

›Sudden severe headache

Coding and terminology

›Serotonin syndrome terminology

›SNOMED CT concept

›Serotonin syndrome

›ICD-10 compatible coding

›Poisoning by selective serotonin reuptake inhibitors, accidental

›Adverse effect of selective serotonin reuptake inhibitors

›Poisoning by other antidepressants, accidental

05Laboratory Tests/lt52

Core safety labs

›Initial lab bundle

›Electrolytes and renal function

›Sodium

›Potassium

›Creatinine

›Bicarbonate

›Liver enzymes

›AST

›ALT

›Creatine kinase

›Rhabdomyolysis risk

›Trend guidance

›Glucose

›Hypoglycemia exclusion

›Complete blood count

›Infection support

›Alternative diagnosis support

Acid base and perfusion

›Metabolic stress labs

›Venous blood gas

›pH

›Lactate

›Arterial blood gas

›PaCO2 in mmHg

›PaO2 in mmHg

›Severe hyperthermia ventilation planning

›Lactate

›Severe agitation marker

›Shock marker

Complications and co-ingestions

›Complication screening

›Urinalysis

›Myoglobinuria suggestion

›Coagulation studies

›DIC concern in severe hyperthermia

›Troponin

›Demand ischemia concern

›Pregnancy test

›Reproductive age

›Toxicology support

›Acetaminophen level

›Intentional ingestion concern

›Salicylate level

›Mixed overdose concern

›Ethanol level

›Mixed intoxication concern

›Urine drug screen

›Sympathomimetic co-use support

›Limited specificity acknowledgement

Interpretation pitfalls

›Lab limitations

›No confirmatory serum serotonin test role

›Creatine kinase elevation non-specific

›Leukocytosis non-specific stress response

›Hyperthermia related transaminitis possible

06Diagnostic Tests/dt67

Scoring Systems

›Diagnostic criteria framework

›Hunter Serotonin Toxicity Criteria

›Serotonergic agent exposure prerequisite

›Prescription serotonergic agent

›Illicit serotonergic agent

›Spontaneous clonus

›Diagnostic if present

›Inducible clonus plus agitation or diaphoresis

›Diagnostic if criteria met

›Ocular clonus plus agitation or diaphoresis

›Diagnostic if criteria met

›Tremor plus hyperreflexia

›Diagnostic if criteria met

›Hypertonia plus temperature >38.0 C plus ocular clonus or inducible clonus

›Diagnostic if criteria met

›Sternbach criteria

›Serotonergic agent exposure

›Recent addition or increase

›No other etiology

›Infection exclusion

›Metabolic exclusion

›Clinical feature cluster

›Mental status change

›Agitation

›Myoclonus

›Hyperreflexia

›Diaphoresis

›Shivering

›Tremor

›Diarrhea

›Incoordination

›Fever

›Evidence framing

›Clinical diagnosis predominance

›No single confirmatory test

›Hunter criteria practical bedside use

›Emphasis on clonus

MRI

›Neuroimaging role

›MRI brain indications

›Persistent focal neurologic deficit

›Concern for encephalitis

›Concern for stroke mimic

›Practical limitations

›Agitation limits feasibility

›Time sensitivity favors stabilization first

›CT role

›CT head indications

›Head trauma concern

›New focal deficit

›Unexplained coma

›CT chest abdomen pelvis considerations

›Alternative source for fever concern

›Evidence framing

›Not diagnostic for serotonin syndrome

›Alternative diagnosis evaluation

Ultrasound

›Point-of-care ultrasound applications

›Cardiac POCUS

›Volume status estimate

›Hyperdynamic state support

›Lung POCUS

›Aspiration pneumonitis support

›Alternative hypoxia cause support

›Bladder ultrasound

›Urinary retention support for anticholinergic mimic

›Evidence framing

›Supportive only

›Complication detection

07Disposition/dispo37

Level of care

›Admission criteria

›Moderate symptoms

›Sustained clonus

›Autonomic instability

›Temperature >= 38.5 C

›Severe symptoms

›Temperature >= 40.0 C

›Delirium

›Seizure

›Rigidity

›Rhabdomyolysis

›ICU criteria

›Active cooling requirement

›High-dose sedative infusion requirement

›Intubation

›Persistent hemodynamic instability

›Observation criteria

›Mild symptoms with improvement

›Resolution of clonus

›Stable vitals

›Reliable follow-up

›Short half-life exposure

›Symptom improvement within 6-12 hours

Discharge readiness

›Discharge criteria

›Normal mental status baseline

›No delirium

›No clonus

›No inducible clonus

›Afebrile

›Stable temperature trend

›Stable heart rate and blood pressure

›No labile instability

›Hydration adequate

›Oral intake tolerated

›Medication plan clarified

›Serotonergic agents held

›Prescriber follow-up arranged

08Treatment/t109

Immediate measures

›First-line strategy

›Offending agent cessation

›All serotonergic agents stopped

›Supportive care

›IV crystalloid for volume depletion

›Electrolyte correction

›Sedation

›Benzodiazepines as first-line for agitation

›Evidence level: Class I (expert consensus) for benzodiazepines in toxicologic agitation

›Temperature control

›External cooling for hyperthermia

›Avoid antipyretics for toxidromic hyperthermia

Benzodiazepines

›Benzodiazepine options

›Diazepam IV

›5-10 mg IV

›Repeat every 5-10 minutes to calm sedation

›Escalation to higher doses for severe agitation

›Lorazepam IV

›1-2 mg IV

›Repeat every 5-10 minutes to calm sedation

›Larger doses for severe agitation

›Midazolam IM

›5-10 mg IM

›Rapid control when no IV access

›Monitoring needs

›Continuous pulse oximetry

›Capnography when available

›Prepared airway support

Serotonin antagonism

›Cyproheptadine use

›Indications

›Moderate symptoms despite benzodiazepines

›Persistent clonus with autonomic instability

›Contraints

›Oral route only

›Nasogastric route option if intubated

›Adult dosing

›12 mg PO or NG loading

›2 mg every 2 hours until clinical response

›Maximum 32 mg per 24 hours

›Maintenance after response

›8 mg PO or NG every 6 hours

›Adverse effects

›Sedation

›Anticholinergic effects

›Evidence level labeling

›Class IIb (limited evidence) for cyproheptadine as adjunctive therapy

Cooling and hyperthermia management

›Temperature management

›External cooling

›Evaporative cooling

›Ice packs to axilla and groin

›Cooling blankets

›IV fluids

›Volume repletion support for heat generation and sweating losses

›Severe hyperthermia pathway

›Temperature >= 40.0 C

›Aggressive sedation

›Intubation consideration

›Neuromuscular paralysis consideration

›Avoided therapies

›Antipyretics

›Limited effect in toxidromic hyperthermia

›Physical restraints alone

›Risk of worsening hyperthermia and rhabdomyolysis

Airway and paralysis for severe cases

›Intubation indications

›Refractory agitation

›Unable to safely manage cooling

›Refractory hyperthermia

›Temperature >= 40.0 C with ongoing heat generation

›Respiratory failure

›Hypoventilation after sedation

›Seizure complications

›Airway protection need

›Neuromuscular blockade

›Non-depolarizing agent preference

›Rocuronium IV 1.0-1.2 mg/kg

›Paralysis to stop muscular heat production

›Vecuronium IV 0.1 mg/kg

›Alternative

›Avoided agent

›Succinylcholine

›Hyperkalemia risk with rhabdomyolysis

›Sedation requirement

›Deep sedation before paralysis

›Continuous analgesia sedation infusion

›Evidence level labeling

›Class I (expert consensus) for paralysis in life-threatening hyperthermia syndromes with ongoing muscle activity

Blood pressure and heart rate control

›Autonomic instability management

›Agitation control first

›Benzodiazepine escalation

›Short-acting agents if needed

›Esmolol IV infusion consideration

›Avoid in hypotension

›Nicardipine IV infusion consideration

›Avoid overshoot hypotension

›Avoided long-acting agents

›Prolonged hypotension risk after resolution

Seizure management

›Seizure treatment

›Benzodiazepines

›Lorazepam IV 0.1 mg/kg

›Typical maximum single dose 4 mg

›Diazepam IV 0.15-0.2 mg/kg

›Typical maximum single dose 10 mg

›Refractory seizures

›Levetiracetam IV 60 mg/kg

›Maximum 4500 mg

›Continuous infusion sedation in ICU

›Avoided therapy

›Phenytoin

›Limited efficacy for toxin-mediated seizures

09Special Populations/sp43

Pregnancy

›Pregnancy considerations

›Maternal stabilization priority

›Oxygenation and perfusion targets

›Medication safety framing

›Benzodiazepines

›Use when clinically required

›Fetal monitoring consideration in viable gestation

›Cyproheptadine

›Limited pregnancy safety data

›Consider when benefits outweigh risks

›Obstetric collaboration

›Continuous fetal monitoring when indicated

›Obstetrics consult for moderate to severe cases

Geriatric

›Older adult considerations

›Baseline polypharmacy risk

›Multiple serotonergic prescriptions

›Higher sensitivity to sedatives

›Lower initial benzodiazepine dosing consideration

›Delirium risk

›Atypical presentation risk

›Less prominent hyperreflexia

›Mixed toxidromes more likely

›Complication risk

›Rhabdomyolysis with prolonged agitation

›Aspiration risk

Pediatrics

›Pediatric considerations

›Weight-based dosing

›Benzodiazepines

›Lorazepam IV 0.05-0.1 mg/kg

›Repeat dosing based on response

›Midazolam IM 0.1-0.2 mg/kg

›Maximum single dose based on local protocol

›Cyproheptadine

›0.25 mg/kg per day PO

›Divide every 6-8 hours

›Maximum 12 mg per day in younger children

›Maximum 32 mg per day in adolescents

›High-risk exposures

›Accidental ingestion

›SSRI dose changes

›Dextromethorphan co-use

›Monitoring intensity

›Lower threshold for admission with sustained clonus

10Background/b39

Epidemiology

›Epidemiologic features

›Common cause category

›Drug interaction

›Polypharmacy

›Overdose

›Onset timing pattern

›Usually within 6 hours of exposure change

›Usually within 24 hours of exposure change

›Under-recognition risk

›Mild cases missed

›Misclassification as anxiety or withdrawal

Pathophysiology

›Mechanism summary

›Excess serotonergic activity

›Central 5-HT receptor overactivation

›Peripheral 5-HT receptor overactivation

›Neuromuscular hyperactivity mechanism

›Increased spinal motor neuron activity

›Hyperthermia mechanism

›Increased muscle activity heat production

›Autonomic dysregulation

›Clinical triad framework

›Mental status change

›Autonomic hyperactivity

›Neuromuscular hyperactivity

Therapeutic Considerations

›Treatment principles

›Supportive care dominance

›Agent cessation

›Sedation

›Cooling

›Antidote role

›Cyproheptadine as adjunct

›Oral route limitation

›Hyperthermia priorities

›Muscle activity suppression

›External cooling

›Early ICU pathway for severe cases

›Evidence labeling

›Class I (expert consensus) for supportive care and benzodiazepines

›Class IIb (limited evidence) for cyproheptadine adjunct

11Patient Discharge Instructions/pdi23

copy discharge instructions

›Discharge instructions

›Diagnosis explanation

›Medication reaction from excess serotonin activity

›Medication plan

›Do not restart serotonergic medications until prescriber review

›Avoid new OTC cough or supplement products without pharmacist review

›Hydration and rest

›Oral fluids

›Avoid intense exercise for 48 hours

›Return to ED immediately

›Fever

›New confusion

›Severe agitation

›Shaking or uncontrollable jerking

›Stiffness

›Fainting

›Chest pain

›Shortness of breath

›Dark urine

›Decreased urination

›Follow-up

›Prescriber contact within 24-72 hours

›Medication reconciliation review

12References/r16

Clinical criteria and landmark descriptions

›Core references

›Hunter Serotonin Toxicity Criteria publication

›Validation and bedside criteria emphasis on clonus

›Sternbach criteria original description

›Earlier diagnostic framework

›Toxicology and critical care reviews

›Supportive care and benzodiazepines as first-line

›Case series and consensus statements

›Cyproheptadine adjunct use

Professional guidance and evidence framing

›Evidence framing references

›Emergency medicine toxicology consensus

›Supportive care as primary therapy

›Critical care hyperthermia management principles

›Sedation plus paralysis for life-threatening hyperthermia

›Medication safety resources

›Serotonergic interaction warnings for linezolid and MAOIs

Learn More: Serotonin syndrome→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.